Patent application number | Description | Published |
20100080268 | CROSSCORRELATION INTERFERENCE MITIGATING POSITION ESTIMATION SYSTEMS AND METHODS THEREFOR - Provided is a method that includes dynamically adjusting a GPS signature code to minimize the interference (e.g., the cross-correlation interference) experienced due to one or more other GPS signals. Further provided is a method that includes adjusting the complexity of an adaptive solution to reduce the time and processing power associated with tracking a GPS signal. | 04-01-2010 |
20110228973 | Methods and systems for digital image security - Methods and systems for securing digital imagery are provided. In one respect, embedding, compression, encryption, data hiding, and other imaging processing techniques and systems may be provided for digital image security. In one non-limiting example, a method for producing a compressed and encrypted image is provided. An image may be converted into a binary bit stream, and the bit stream may be decomposed into a plurality of segments. A binary sequence based on a first key may be generated and may be used to generate a code matrix. A distance between the code matrix and the distance may be determined for each of the plurality of segments. Using a combined first and second key, a compressed and encrypted image may be obtained. | 09-22-2011 |
20130117019 | Remote Laboratory Gateway - A remote laboratory gateway enables a plurality of students to access and control a laboratory experiment remotely. Access is provided by an experimentation gateway, which is configured to provide secure access to the experiment via a network-centric, web-enabled interface graphical user interface. Experimental hardware is directly controlled by an experiment controller, which is communicatively coupled to the experimentation gateway and which may be a software application, a standalone computing device, or a virtual machine hosted on the experimentation gateway. The remote laboratory of the present specification may be configured for a software-as-a-service business model. | 05-09-2013 |
Patent application number | Description | Published |
20130017249 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY - Here described are compounds consisting of the structure | 01-17-2013 |
20130022665 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS - Here described are compounds of formula I: | 01-24-2013 |
20130071467 | RETINOID-LIPOSOMES FOR TREATING FIBROSIS - What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 expression, including fibrosis. | 03-21-2013 |
20130071478 | RETINOID-LIPOSOMES FOR ENHANCING MODULATION OF HSP47 EXPRESSION - What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH | 03-21-2013 |
20130115274 | METHOD OF PRODUCING LIPID NANOPARTICLES FOR DRUG DELIVERY - What is described is a method for preparing a liposome that efficiently encapsulates a negatively charged therapeutic polymer, e.g., siRNA. The process involves preparing a lipid mixture comprising a cationic lipid in a water miscible organic solvent, such as ethanol, at a concentration of 2.3 mg/ml, and adding this solution to the polymer dissolved in water to a final concentration of 35% ethanol in water. The final charge ratio of drug:lipid is 1:2.5. The resulting nanoparticles have a mean size of 50 to 150 nm. | 05-09-2013 |
20130171127 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE - The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue. | 07-04-2013 |
20130171240 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS - Disclosed is a stellate cell-specific drug carrier comprising a stellate cell-specific amount of a retinoid derivative and/or a vitamin A analogue, and a drug carrier component other than the retinoid derivative and/or a vitamin A analogue. Also disclosed in a medicine comprising the stellate cell-specific drug carrier, and a drug in an amount effective for controlling the activity or growth of stellate cells. | 07-04-2013 |
20130210744 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST - Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid and/or derivative thereof; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anticancer-associated fibroblast composition; and a method for treatment of cancer. | 08-15-2013 |
20130330401 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS - The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes. | 12-12-2013 |
20140294934 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS - Here described are compounds of formula I: | 10-02-2014 |
20140356413 | RETINOID-LIPOSOMES FOR TREATING FIBROSIS - What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis. | 12-04-2014 |
20160074514 | Lipids for Therapeutic Agent Delivery Formulations - The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes. | 03-17-2016 |